


TRANSGENE BIOTEK LIMITED
UNAUDITED STANDALONE BALANCE SHEET AS AT 30TH SEP 2015

(Amounts in Indian rupees, except share data and where otherwise stated)

Particulars	Note	As at 30 th Sep 2015	As at 31st March 2015
EQUITY AND LIABILITIES			
Shareholder's Funds			
Share Capital	1	757,700,000	757,700,000
Reserves and Surplus	2	942,149,107	1,023,786,052
Non-Current Liabilities			
Long-term borrowings	3	62,668,640	62,668,640
Long term provisions	4	1,208,786,442	1,208,786,442
Current Liabilities			
Short-term borrowings	5	87,024,205	80,720,490
Trade payables	6	8,816,717	156,046,922
Other current liabilities	7	11,255,436	13,555,001
Total Equity and Liabilities		3,078,400,548	3,303,263,547
ASSETS			
Non-current assets			
Fixed assets			
(i) Tangible assets		45,180,786	51,413,446
(ii) Intangible assets		1,512,358,482	1,582,627,751
Capital work-in-progress		2,890,306	2,890,306
Non-current investments	8	922,009,728	922,009,728
Long term loans and advances	9	241,907,253	241,907,253
Other non-current assets	10	319,885,401	319,885,401
Current assets			
Inventories	11	661,543	661,543
Trade receivables	12	15,864,605	163,891,004
Cash and cash equivalents	13	389,791	301,386
Short-term loans and advances	14	17,252,654	17,675,728
Total Assets		3,078,400,548	3,303,263,547

Note: The notes referred to above are an integral part of the Balance Sheet.

As per our report attached
For Gopal & Rajan
Chartered Accountants
Firm Registration No. 0953S
K. Goutham Subbaiah
Partner
Membership No: 203237



For and on behalf of the board of Directors
Transgene Biotek limited


Dr. K. Koteswara Rao
Managing Director

Place: Hyderabad
Date: 13/11/2015

For TRANSGENE BIOTEK LTD.



MANAGING DIRECTOR

TRANSGENE BIOTEK LIMITED
UNAUDITED STANDALONE PROFIT AND LOSS ACCOUNT FOR THE HALF YEAR ENDED 30th SEP 2015
 (All amounts in Indian rupees, except share data and where otherwise stated)

Particulars	Note	For the half year ended 30 Sep 2015	For the year ended 31st March 2015
INCOME			
Revenue from operations	15	1,019,478	3,147,660
Other Income	16	410,146	180,000
Total Income		1,429,624	3,327,660
EXPENSES			
Cost of materials consumed	17	-	123,278
Purchase of Traded goods	18	-	-
(Increase)/decrease in finished stock	19	-	18,975
Employee benefit expenses	20	3,526,863	10,421,398
Financial costs	21	12,686	3,597,413
Depreciation and amortization expenses	22	86,328,489	171,805,093
Other expenses	23	3,025,090	7,660,707
Total Expenses		92,893,129	193,626,864
Profit before exceptional and extraordinary items and tax		(91,463,505)	(190,299,204)
Exceptional and extraordinary items		-	-
Profit before extraordinary items and tax		(91,463,505)	(190,299,204)
Extraordinary items		-	-
Prior Period Expenditure/(Income)		-	60,241
Profit before tax		(91,463,505)	(190,359,445)
Tax expense:			
Current tax expenses		-	-
Deferred tax charge / (credit)		-	-
Profit for the period		(91,463,505)	(190,359,445)
Earnings per Equity Share (Equity shares of par value Rs. 10 each)			
Basic		(1.21)	(2.51)
Diluted		(1.21)	(2.51)
Number of shares used in computing earnings per share			
Basic		75,770,000	75,770,000
Diluted		75,770,000	75,770,000

Note: The notes referred to above are an integral part of the Statement Profit and Loss

As per our report attached
 For Gopal & Rajan
 Chartered Accountants
 Firm Registration
 K. Goutham Subbarao
 Partner
 Membership No:203237



For and on behalf of the board of Directors
Transgene Biotek limited


 Dr. K. Koteswara Rao
 Managing Director

Place: Hyderabad
 Date: 13/11/2015

For TRANSGENE BIOTEK LTD.


MANAGING DIRECTOR

TRANSGENE BIOTEK LIMITED
Notes to financial statements for the Half year ended 30th Sep 2015
 (All amounts in Indian rupees, except share data and where otherwise stated)

I. SHARE CAPITAL

PARTICULARS	As at 30 Sep 2015	As at 31 March 2015
Authorised :		
Equity Shares		
(7,60,00,000 Shares of Rs. 10 each)	760,000,000	760,000,000
(Previous year 7,60,00,000 equity shares)		
	760,000,000	760,000,000
Issued, subscribed and paid-up :		
Equity Shares		
(7,57,70,000 shares of Rs. 10 each fully paid up)	757,700,000	757,700,000
(Previous year 7,57,70,000 equity shares)		
Share Application Money	-	-
	757,700,000	757,700,000

The Company has only one class of shares referred to as equity shares having a par value of Rs. 10/- each. Each holder of one equity share is entitled to one vote per share.

In the event of the liquidation of the Company, the holders of shares shall be entitled to receive any of the remaining assets of the Company, after distribution of all preferential amounts. However no such preferential amounts exists currently. The amount distributed will be in proportion to the number of equity shares held by the shareholders

The reconciliation of the number of equity shares outstanding is set out below:

Particulars	As at 30 Sep 2015		As at 31 March 2015	
	Number of shares	Amount	Number of shares	Amount
Shares outstanding at the beginning of year	75,770,000	757,700,000	65,770,000	657,700,000
Shares Issued during the year	-	-	10,000,000	100,000,000
Shares outstanding at the end of the year	75,770,000	757,700,000	75,770,000	757,700,000

The details of shareholder holding more than 5% equity shares is set below:

Name of the Shareholders	As at 30 Sep 2015		As at 31 March 2015	
	Number of shares	% of Shareholding	Number of shares	% of Shareholding
Dr. K. Koteswara Rao	15,211,902	20.08%	15,211,902	0
Polavarapu vikram	8,732,171	11.52%	8,732,171	0
The Bank of New York Mellon, DR	7,970,000	10.52%	7,970,000	0

As per records of the Company, including its register of shareholders/ members and other declarations received from shareholders regarding beneficial interest, the above shareholding represents both legal and beneficial ownership of shares

2. RESERVES AND SURPLUS

PARTICULARS	As at 30 Sep 2015	As at 31 March 2015
Security Premium account :		
Balance brought forward	1,388,092,501	1,388,092,501
Additions during the year	-	-
	1,388,092,501	1,388,092,501
Less: Expenses incurred for issue of securities	-	-
Closing balance at the end of the year	1,388,092,501	1,388,092,501
Capital Reserve		
Balance Brought forward	891,265,401	891,265,401
Additions during the year	-	-
Closing balance at the end of the year	891,265,401	891,265,401
Warrants Forfeiture reserves		
Balance brought forward	12,250,000	12,250,000
Additions during the year	-	-
Closing balance at the end of the year	12,250,000	12,250,000
Exchange Translation Reserve	116,288,237	116,288,237
Profit & Loss account		
Balance brought forward	-1,384,110,087	-1,193,750,642
Add : Profit during the year	-91,463,505	-190,359,445
Add: Increase in Retained Earnings Due to revision of Depreciation	9,826,559	-
Closing balance in P & L Account	-1,465,747,032	-1,384,110,087
	942,149,107	1,023,786,052

For TRANSGENE BIOTEK LTD.

MANAGING DIRECTOR

3. LONG TERMS BORROWINGS

PARTICULARS	As at 30 Sep 2015	As at 31 March 2015
Term Loan from Dept. Bio technology, Ministry of Science and Technology, Govt. of India	44,247,901	44,247,901
Working Capital Term Loan from UBI	18,420,739	18,420,739
	<u>62,668,640</u>	<u>62,668,640</u>

* Term Loans are secured by first pari passu charge on all the present and future fixed assets both movable and immovable property of the Company

** Term loan from Department of Bio Technology (DBT), Ministry of Science and Technology are secured by the whole of movable and immovable properties acquired from the loan sanctioned by the DBT under SBIRI scheme.

4. LONG TERM PROVISIONS

PARTICULARS	As at 30 Sep 2015	As at 31 March 2015
Provision for Employees Retirement Benefits	411,958	411,958
Provision for Fringe Benefit Tax	58,368	58,368
Income Tax provision earlier years	56,102,138	56,102,138
Provision for Investments	1,152,213,978	1,152,213,978
	<u>1,208,786,442</u>	<u>1,208,786,442</u>

5. SHORT TERM BORROWINGS

PARTICULARS	As at 30 Sep 2015	As at 31 March 2015
<i>Loans repayable on demand from parties</i>		
From related parties	44,289,862	37,338,656
From others	42,734,343	43,381,834
	<u>87,024,205</u>	<u>80,720,490</u>

6. TRADE PAYABLES

PARTICULARS	As at 30 Sep 2015	As at 31 March 2015
Dues of Micro and Small Enterprises	-	-
Dues other than Micro and Small Enterprises	8,816,717	156,046,922
	<u>8,816,717</u>	<u>156,046,922</u>

7. OTHER CURRENT LIABILITIES

PARTICULARS	As at 30 Sep 2015	As at 31 March 2015
Other payables	8,866,891	10,274,942
Statutory Liabilities	2,388,545	3,280,059
	<u>11,255,436</u>	<u>13,555,001</u>

8. NON CURRENT INVESTMENTS

PARTICULARS	As at 30 Sep 2015	As at 31 March 2015
In Subsidiaries, Un-Quoted <i>Transgene Biotech HK Limited</i> (16,952,001 Shares of US\$ 1.00 each)	922,009,728	922,009,728
	<u>922,009,728</u>	<u>922,009,728</u>

9. LONG TERM LOANS AND ADVANCES

PARTICULARS	As at 30 Sep 2015	As at 31 March 2015
(Unsecured, considered good except stated Otherwise)		
Advance for acquiring for Technologies/Patents/Know-how	233,452,253	233,452,253
Earnest Money Deposit with Govt/ Other authorities	8,455,000	8,455,000
	<u>241,907,253</u>	<u>241,907,253</u>

For TRANSGENE BIOTEK LTD.


MANAGING DIRECTOR

10. OTHER NON-CURRENT ASSETS

PARTICULARS	As at 30 Sep 2015	As at 31 March 2015
(Unsecured, considered good except stated Otherwise)		
Product Development Expenditure	302,408,768	302,408,768
Technology Development cost	17,476,633	17,476,633
	319,885,401	319,885,401

11. INVENTORIES

PARTICULARS	As at 30 Sep 2015	As at 31 March 2015
(Value at lower of cost and net realizable value)		
Raw Material and Consumables	521,828	521,828
Finished Goods	139,715	139,715
	661,543	661,543

12. TRADE RECEIVABLES

PARTICULARS	As at 30 Sep 2015	As at 31 March 2015
(Unsecured, considered good except stated Otherwise)		
	-	-
Debts outstanding for a period exceeding six months from the date they are due for payment	15,864,605	163,891,004
Other Debts		
	15,864,605	163,891,004

13. CASH AND CASH EQUIVALENTS

PARTICULARS	As at 30 Sep 2015	As at 31 March 2015
Cash on Hand	46,127	17,467
Balance with Schedule Banks		
In current accounts	312,965	253,221
In deposit accounts	698	698
Balance with Non Scheduled Banks	30,000	30,000
	389,791	301,386

PARTICULARS	As at 30 Sep 2015	As at 31 March 2015
Balance with Banks in current accounts		
Axis Bank Ltd - 911020057235469	98,056	24,823
Axis Bank Ltd - 913020044397910	-	1,941
Bank of India -Nidadavolu	182,030	190,186
Bank of India -Tadepalligudem	4,744	8,136
Indus Ind Bank	10,500	10,500
Union Bank of India	7,636	7,636
Yes Bank	10,000	10,000
Indian Bank		-
	312,965	253,221
In deposit accounts		
Union Bank of India (SIBRI)	698	698
	698	698
Balance with Non Scheduled Banks		
HSBC	30,000	30,000
	30,000	30,000
	343,664	283,919

14. SHORT TERM LOANS AND ADVANCES

PARTICULARS	As at 30 Sep 2015	As at 31 March 2015
Unsecured, Considered good		
Rent Deposits	50,000	250,000
Advance to Suppliers	9,252,938	9,493,644
CENVAT Credit Recievable	159,273	129,614
With Holding Tax Receivables	1,065,264	1,065,264
VAT Credit Recievable	47,875	59,902
Capital advance	6,677,303	6,677,303
	17,252,654	17,675,727

For TRANSGENE BIOTEK LTD.

 MANAGING DIRECTOR

15. REVENUE FROM OPERATIONS

PARTICULARS	As at	As at
	30 Sep 2015	31 March 2015
Diagnostic Services	1,019,478	3,147,660
Sales of Products (Net of Taxes and Duties)	-	-
	<u>1,019,478</u>	<u>3,147,660</u>

16. OTHER INCOME

PARTICULARS	As at	As at
	30 Sep 2015	31 March 2015
Facility Rental Charges	410,146	180,000
Interest earned	-	-
Forex gain on Capital Advances	-	-
Miscellaneous Income	-	-
	<u>410,146</u>	<u>180,000</u>

17. COST OF MATERIAL CONSUMED

PARTICULARS	As at	As at
	30 Sep 2015	31 March 2015
Opening Stock	521,828	563,683
Add: Purchases	-	81,423
	<u>521,828</u>	<u>645,106</u>
Less: Closing Stock	521,828	521,828
	<u>-</u>	<u>123,278</u>
Less: Material Consumed for Product Development	-	-
	<u>-</u>	<u>123,278</u>

18. PURCHASE OF TRADED GOODS

PARTICULARS	As at	As at
	30 Sep 2015	31 March 2015
Opening Stock	-	-
Add: Purchases	-	-
Less: Closing Stock	-	-
	<u>-</u>	<u>-</u>

19. (INCREASE)/DECREASE IN FINISHED GOODS

PARTICULARS	As at	As at
	30 Sep 2015	31 March 2015
<i>Traded, Raw material and Finished Goods</i>		
<i>Inventories at the end of the year</i>		
Traded Goods	-	-
Finished Goods	139,715	139,715
Raw material and Consumables	-	-
	<u>139,715</u>	<u>139,715</u>
<i>Inventories at the beginning of the year</i>		
Raw material and Consumables	-	-
Finished Goods	139,715	158,690
	<u>139,715</u>	<u>158,690</u>
	<u>-</u>	<u>18,975</u>

20. EMPLOYEE BENEFIT EXPENSES


PARTICULARS	As at	As at
	30 Sep 2015	31 March 2015
Salaries, wages and bonus	3,161,828	7,971,394
Contribution to provident fund and other funds	120,273	291,902
Gratuity expenses	-	-
Leave Encashment expenses	-	-
Staff welfare expenses	244,762	2,158,102
	<u>3,526,863</u>	<u>10,421,398</u>

21. FINANCIAL COSTS

PARTICULARS	As at	As at
	30 Sep 2015	31 March 2015
Interest to Banks and Financial institutions	-	3,547,901
Bank charges	12,686	49,512
	<u>12,686</u>	<u>3,597,413</u>

22. DEPRECIATION AND AMORTIZATION EXPENSE

PARTICULARS	As at	As at
	30 Sep 2015	31 March 2015
Depreciation as per IX note	86,328,489	171,805,093
Depreciation transferred to Product Development exp.	-	-
	<u>86,328,489</u>	<u>171,805,093</u>

For TRANSGENE BIOTEK LTD.

 MANAGING DIRECTOR

23. OTHER EXPENSES

PARTICULARS	As at 30 Sep 2015	As at 31 March 2015
Conversion Charges	-	-
Consumables	-	70,237
Power and Fuel	527,113	1,600,621
Rates, Taxes and Fees	372,977	346,874
Printing and Stationery	47,295	100,219
Postage and Telephone	96,341	174,028
Insurance	-	20,190
Legal and Professional charges	901,600	461,767
Directors sitting fee	-	-
Remuneration to Auditors	35,048	197,413
Sales Commission	-	-
Rebate and Discounts	28,430	96,558
Travelling, Transport and Conveyance	206,385	612,899
Vehicle maintenance and hire charges	-	132,000
Referral expenses	-	228,516
Advertisement	78,600	90,900
Listing Fee	-	-
R & D Expenses	-	761,503
Repairs & Maintenance	96,351	240,725
Lab Maintenance	118,086	624,530
Office Maintenance	56,786	157,429
Security Charges	-	140,032
Administration expenses	-	125,000
Business promotion expenses-HO	435,680	326,859
Business Promotion expenses-Lab Service Centres	-	1,103,531
Misc. Expenses	24,398	48,876
Interest on Statutory payments	-	-
	3,025,090	7,660,707

As per our report attached

For Gopal & Rajan
Chartered Accountants
Firm Registration No.

K. Goutham Subbaiah
Partner
Membership No.203237

Place: Hyderabad
Date: 13/11/2015



For and on behalf of the board of Directors
Transgene Biotek limited


Dr. K. Koteswara Rao
Managing Director

For TRANSGENE BIOTEK LTD.

MANAGING DIRECTOR

ANNEXURE IX TO CLAUSE 41

(Rs. In Lacs)

Standalone Statement of Assets and Liabilities		As at Half year ended 30th Sep 2015	As at year ended 31st March 2015
		(Unaudited)	(Audited)
A EQUITY AND LIABILITIES			
1	Share Holders Fund		
	(a) Share Capital	7,577.00	7,577.00
	(b) Reserves and Surplus	9,421.49	10,237.86
	(c) Money Received against Share Warrants	-	-
	Sub Total - Share Holders' Fund	16,998.49	17,814.86
2	Share Application Money pending allotment	-	-
3	Minority Interest	-	-
4	Non-Current Liabilities		
	(a) Long Term Borrowings	626.69	626.69
	(b) Deferred Tax Liabilities (Net)	-	-
	(c) Other Long-Term Liabilities	-	-
	(d) Long-term Provisions	12,087.86	12,087.86
	Sub-Total- Non Current Liabilities	12,714.55	12,714.55
5	Current Liabilities		
	(a) Short Term Borrowings	870.24	807.20
	(b) Trade Payables	88.17	1,560.47
	(c) Other Current Liabilities	112.55	135.55
	(d) Short-term Provisions	-	-
	Sub-Total- Current Liabilities	1,070.96	2,503.22
	TOTAL EQUITY AND LIABILITIES	30,784.01	33,032.64
B ASSETS			
1	Non-Current Assets		
	(a) Fixed Assets	15,604.30	16,369.32
	(b) Goodwill on Consolidation	-	-
	(c) Non- Current Investments	9,220.10	9,220.10
	(d) Deferred Tax Assets (Net)	-	-
	(e) Long-term Loans and Advances	2,419.07	2,419.07
	(f) Other Non Current Assets	3,198.85	3,198.85
	Sub - total -Non Current Assets	30,442.32	31,207.34
2	Current Assets		
	(a) Current Investments	-	-
	(b) Inventories	6.62	6.62
	(c) Trade Receivables	158.65	1,638.91
	(d) Cash and Cash Equivalents	3.90	3.01
	(e) Short-term Loans and Advances	172.53	176.76
	(f) Other Current Assets	-	-
	Sub-total- Current Assets	341.69	1,825.30
	TOTAL ASSETS	30,784.01	33,032.64

0.00
(0.00)

For and on behalf of the Board of Directors


Dr K Koteswara Rao
Chairman & Managing DirectorPlace: Hyderabad
Date: 13/11/2015

Annexure IV to Clause 41
Reporting of Segment wise Revenue, Results and Capital Employed along with the quarterly results

(Rs. In Lakhs)

S.No	PARTICULARS	Quarter Ended 30.09.2015 (Unaudited)	Quarter Ended 30.06.2015 (Unaudited)	Quarter Ended 30.09.2014 (Audited)	For the half year ended 30.09.2015 (Unaudited)	For the half year ended 30.09.2014 (Audited)	Previous year Ended 31.03.2015 (Audited)
1	SEGMENT REVENUE	Rs.	Rs.	Rs.		Rs.	Rs.
	a)Segment -A Diagnostic Services	5.53	4.67	8.83	10.19	19.35	31.48
	b)Segment -B Agri Division	-	-	-	-	-	-
	c) Segment-C Bulk Drugs Trading	-	-	-	-	-	-
	d)Segment-D CRO Services	2.52	1.58	-	4.10	-	1.80
	e) Segment-E API-DHA	-	-	-	-	-	-
	Total:	8.05	6.25	8.83	14.30	19.35	33.28
	Less: Inter Segement Revenue	-	-	-	-	-	-
	Net Sales/income From Operation	8.05	6.25	8.83	14.30	19.35	33.28
2	SEGMENT RESULTS						
	(Profit /Loss Before Tax & Interst from each Segment)						
	a)Segment -A Diagnostic services	0.20	0.36	-0.39	0.56	-0.44	-3.95
	b)Segment -B Agri Division	-	-	-	-	-	-
	c) Segment-C Bulk Drugs Trading	-	-	-	-	-	-
	d)Segment-D ORC Services	-	-	-	-	-	-
	e) Segment-E API-DHA	-	-	-491.71	-	-959.14	-1,854.58
	f) R & D Expenses	-0.56	-0.63	-2.48	-1.18	-6.36	-9.04
	Total Segmental Result	-0.36	-0.26	-494.58	-0.62	-965.94	-1,867.57
	Other Income	-	-	-	-	-	-
	Total	-0.36	-0.26	-494.58	-0.62	-965.94	-1,857.57
	Less: Interest & Finance Charges	0.04	0.09	-	0.13	-	35.97
	Less:Unallocable expenses	-	-	-	-	-	-
	Exceptional items-forex fluctuation(gain)/Loss	-	-	-	-	-	-
	Total Profit/Loss Before Tax	-0.39	-0.35	-494.58	-0.74	-965.94	-1,903.55
3	CAPITAL EMPLOYED						
	a)Segment - A Diagnostic services	324.83	324.83	324.83	324.83	324.83	324.83
	b)Segment - B Agri Division	-	-	-	-	-	-
	c) Segment-C Bulk Drugs	24,090.93	24,090.93	24,090.93	24,090.93	24,090.93	24,090.93
	Total	24,415.76	24,415.76	24,415.76	24,415.76	24,415.76	24,415.76

Place: Hyderabad
Date: 13/11/2015

For TRANSGENE BIOTEK LTD.


MANAGING DIRECTOR

TRANSGENE BIOTEK LIMITED
68,69,&70, ANRICH INDUSTRIAL AREA
BOLLARAM, MEDAK DISTRICT
STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE HALF YEAR ENDED 30.09.2015

(Rs. In Lakhs)

Particulars	Quarter ended 30.09.2015	Quarter ended 30.06.2015	Quarter ended 30.09.2014	For the half year ended 30.09.2015	For the half year ended 30.09.2014	For Previous year ended 31.03.2015
	Unaudited	Unaudited	Audited	(Unaudited)	(Audited)	Audited
1 (a) Net Sales/Income from Operations	8.05	6.25	8.83	14.30	19.35	33.28
(b) Other Operating Income	-	-	-	-	-	-
2. Expenditure						
a. Increase/decrease in stock in trade and work in progress	-	-	-	-	-	0.19
b. Consumption of raw materials	-	-	0.94	-	2.80	1.23
2 c. Purchase of traded goods	-	-	-	-	-	-
d. Employees cost	12.85	22.42	47.13	35.27	71.46	119.21
e. Depreciation	434.95	428.33	432.36	863.28	861.38	1,718.05
f. Other expenditure	19.18	11.07	22.94	30.25	49.54	82.48
Total	466.98	461.83	503.37	928.80	985.18	1,921.17
3 Profit from Operations before Other Income, Interest and Exceptional Items (1-2)	-458.93	-455.58	-494.54	-914.51	-965.83	-1,887.90
4 Other Income	-	-	-	-	-	-
5 Profit / (loss) from Ordinary activities before finance cost and exceptional items(3+4)	-458.93	-455.58	-494.54	-914.51	-965.83	-1,887.90
6 Finance Cost	0.04	0.09	0.04	0.13	0.11	32.40
7 Profit / (loss) from ordinary activities after finance cost but before Exceptional Items (5-6)	-458.97	-455.67	-494.58	-914.64	-965.94	-1,920.30
8 Prior Period Expenses/ (income)	-	-	-	-	-	0.60
9 Profit (+)/ Loss (-) from Ordinary Activities before tax (7+8)	-458.97	-455.67	-494.58	-914.64	-965.94	-1,920.90
10 Tax expense	-	-	-	-	-	-
11 Net Profit (+)/ Loss (-) from Ordinary Activities after tax (9-10)	-458.97	-455.67	-494.58	-914.64	-965.94	-1,920.90
12 Extraordinary Item (net of tax expense if any)	-	-	-	-	-	-
13 Net Profit(+)/ Loss(-) for the period (11-12)	-458.97	-455.67	-494.58	-914.64	-965.94	-1,920.90
14 Share of profit/(loss) of associates	-	-	-	-	-	-
15 Minority Interest	-	-	-	-	-	-
16 Net Profit(+)/ Loss(-) after taxes,Minority interest and share of profit/(Loss) of associates (13-14-15))	-458.97	-455.67	-494.58	-914.64	-965.94	-1,920.90
17 Paid-up equity share capital (Face value of share of Rs 10/- each)	7,577.00	7,577.00	7,577.00	7,577.00	7,577.00	7,577.00
No of Shares	75,770,000	75,770,000	75,770,000	75,770,000	75,770,000	75,770,000
18 Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	9,421.49	9,764.89	25,283.24	9,421.49	25,283.24	12,141.45
Earnings Per Share (EPS)						
19 a) Basic EPS before Extraordinary items for the period, for the year to date and for the previous year (not to be annualized)	-0.06	-0.06	-0.65	-0.12	-1.27	-2.54
b) Diluted EPS before Extraordinary items for the period, for the year to date and for the previous year (not to be annualized)	-0.06	-0.06	-0.65	-0.12	-1.27	-2.54
c) Basic EPS after Extraordinary items for the period, for the year to date and for the previous year (not to be annualized)	-0.06	-0.06	-0.65	-0.12	-1.27	-2.54
d) Diluted EPS after Extraordinary items for the period, for the year to date and for the previous year (not to be annualized)	-0.06	-0.06	-0.65	-0.12	-1.27	-2.54
Public Shareholding						
20 No. of shares	59,342,098	59,342,098	59,342,098	59,342,098	59,342,098	59,342,098
Percentage of shareholding	78.32	78.32	78.32	78.32	78.32	78.32
Promoters and promoter group Shareholding **	16,427,902	16,427,902	16,427,902	16,427,902	16,427,902	16,427,902
a) Pledged/Encumbered	-	-	-	-	-	-
Number of shares	-	-	-	-	-	-
Percentage of shares (as a % of the total shareholding of promoter and promoter group)	-	-	-	-	-	-
21 Percentage of shares (as a % of the total share capital of the company)	-	-	-	-	-	-
b) Non-encumbered	-	-	-	-	-	-
Number of Shares	16,427,902	16,427,902	16,427,902	16,427,902	16,427,902	16,427,902
Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00	100.00
Percentage of shares (as a % of the total share capital of the company)	21.68	21.68	21.68	21.68	21.68	21.68

Notes to the Results

- DHA Sales in powder form are to start soon in commercial quantities.
- Oral Insulin and oral delivery platform projects are proceeding well with continuing discussions with multinational companies.
- Performance of Transgene Medical Centers, the diagnostic division, has remained stagnant and the management has decided to dispose them off.
- No. of Investor complaints pending at the beginning of the quarter - Nil; received during the quarter - Nil; resolved during the quarter - Nil; pending unresolved at the end of the quarter - Nil.
- No. of Investor complaints pending at the beginning of the quarter - Nil; received during the quarter - Nil; resolved during the quarter - Nil; pending unresolved at the end of the quarter - Nil.
- The auditors have carried out a limited review of the above financial results and these were reviewed by the Audit committee and taken on record by the Board of Directors of the Company at their meeting held on 13th November 2015.

Place: Hyderabad
Date: 13/11/2015

For TRANSGENE BIOTEK LTD.

MANAGING DIRECTOR

LIMITED REVIEW REPORT

To,

The Board of Directors
M/s Transgene Biotek Limited
Hyderabad

1. We have reviewed the accompanying statements of unaudited financial result of **M/s Transgene Biotek Limited** for the quarter ended **30th September, 2015**, except for the disclosures regarding 'Public Shareholding' and Promoter Group Shareholding' and 'Number of Investors Complaints' which have been traced from disclosures made by the management but have not audited by us. This statement has been prepared by the Company pursuant to clause 41 of the Listing Agreement with the Stock Exchange in India, which has been initialed by us for identification purpose. The Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Financial Statements are free of Material Misstatement.
3. A review is limited primarily to inquiries of company personnel and analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Un-audited Financial results for the **Quarter ended 30th September, 2015** prepared in accordance with applicable Accounting Standards and other recognized accounting practices and policies and has not disclosed the information required to be disclosed in terms of clause 41 of the listing agreement including the manner in which is to be disclosed.

Place: Hyderabad

Date: 13th November, 2015.

For GOPAL & RAJAN
Chartered Accountants



K. GOUTHAM SUBBIAH
Partner
M.No.203237
FRN.000953S